Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research report released on Tuesday,Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent BioSolutions’ Q1 2025 earnings at $0.27 EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

A number of other analysts have also issued reports on the stock. Benchmark increased their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Monday, February 17th.

Emergent BioSolutions Trading Up 0.6 %

NYSE:EBS opened at $5.84 on Tuesday. Emergent BioSolutions has a 1 year low of $1.82 and a 1 year high of $15.10. The business has a fifty day moving average of $9.38 and a 200-day moving average of $9.00. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock has a market cap of $316.22 million, a price-to-earnings ratio of -1.42 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the firm earned ($0.77) earnings per share. Equities analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp increased its position in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 1,713,200 shares during the period. Oak Hill Advisors LP bought a new position in Emergent BioSolutions during the third quarter valued at about $9,296,000. Millennium Management LLC raised its holdings in Emergent BioSolutions by 83.0% in the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock valued at $14,167,000 after acquiring an additional 671,947 shares in the last quarter. Invesco Ltd. lifted its position in shares of Emergent BioSolutions by 70.9% in the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after acquiring an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after purchasing an additional 444,790 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.